Revenues

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

The following table presents a summary of total revenues (in thousands):

	Year Ended December 31,
	2024		2023		2022
Xywav	$	1,473,202	$	1,272,977	$	958,425
Xyrem	233,816		569,730		1,020,453
Epidiolex/Epidyolex	972,423		845,468		736,398
Sativex	18,877		19,668		16,825
Sunosi1	—		—		28,844
Total Neuroscience	2,698,318		2,707,843		2,760,945
Rylaze/Enrylaze	410,846		394,226		281,659
Zepzelca	320,318		289,533		269,912
Defitelio/defibrotide	216,565		184,000		194,290
Vyxeos	162,595		147,495		127,980
Ziihera	1,051		—		—
Total Oncology	1,111,375		1,015,254		873,841
Other	11,471		13,846		6,643
Product sales, net	3,821,164		3,736,943		3,641,429
High-sodium oxybate AG royalty revenue	217,575		75,918		—
Other royalty and contract revenues	30,211		21,343		17,945
Total revenues	$	4,068,950	$	3,834,204	$	3,659,374

____________________________

(1) Divestiture of Sunosi U.S. was completed in May 2022.

The following table presents a summary of total revenues attributed to geographic sources (in thousands):

	Year Ended December 31,
	2024		2023		2022
United States	$	3,660,109	$	3,489,977	$	3,370,379
Europe	312,706		269,243		239,638
All other	96,135		74,984		49,357
Total revenues	$	4,068,950	$	3,834,204	$	3,659,374

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:

	Year Ended December 31,
	2024		2023		2022
ESSDS	42	%	48	%	56	%
McKesson	12	%	11	%	11	%

Financing and payment

Our payment terms vary by the type and location of our customer, but payment is generally required in a term ranging from 30 to 65 days.